Published: August 27, 2008
Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
SCOTTSDALE, Ariz., Aug. 27 /PRNewswire/ -- MedPredict has published a new
report in its oncology series entitled "Thought Leader Insight & Analysis:
Breast Cancer," designed to provide critical strategic insight for pharma and
biotech companies with a stake in the market for diagnostics and treatments in
this disease area. MedPredict interviewed renowned North American and
European breast cancer thought leaders to identify the most promising
candidates in clinical development, as well as explore unmet needs. They
address the following questions:
-- Has Novartis jumped ahead of Amgen in developing a breast cancer drug
that provides a mortality benefit and preserves bone? MedPredict's panel
debates the implications of Novartis' positive zoledronic acid (Zometa) data
presented at ASCO 2008.
-- How prevalent is osteonecrosis of the jaw with antiresorptives, and how
will this affect their usage in breast cancer?
-- How is triple negative breast cancer being treated, and where are the
opportunities for development in this subtype?
-- What are the best approaches for development of inhibitors of mTOR,
IGF1R, EGFR, PARP-1, HSP90, Src, angiogenesis, FA2, hedgehog, and vaccines?
"This report will provide essential strategic insight for those involved
in development of breast cancer therapies," according to MedPredict President
Dr. Jeffrey Berk. "Our report discusses ongoing clinical programs, and offers
insight into which of the many new drugs in development are likely to be
significant improvements over current options."
Companies included in this report: Abbott (ABT-888, ABT-999, A-928605),
Abraxis/AstraZeneca (Abraxane), Amgen (denosumab, AMG-479), AstraZeneca
(Arimidex, olaparib, saracatinib), Bayer-Schering (Bonefos), BiPar (BSI-201,
BSI-401), Boehringer Ingelheim (Tovok), Bristol-Myers Squibb (brivanib,
BMS-754807, Sprycel, Ixempra), BMS/Imclone (Erbitux), Exelixis (XL-765,
XL-647), Genentech (Avastin, GDC-0941, Herceptin, pertuzumab,
trastuzumab-DM1), GlaxoSmithKline (Tykerb), Imclone (IMC-A12, IMC-1121B),
Kosan (tanespimycin), Merck (Fosamax, odanacatib, MK-0646), Myriad
(BRCA1/BRCA2 Screening), Merck/Ariad (deforolimus), Novartis (Zometa, Femara,
everolimus, patupilone, TAE-266), OSI (OSI-906), Pfizer (Aromasin, Sutent,
Tarceva, CP-751871), Pierre Fabre (Javlor), Roche/GSK (Boniva), Roche
(Xeloda), Sanofi-Aventis (AVE-1642), Schering-Plough (SCH-717454), and Wyeth
(Torisel, neratinib).
The full report can be purchased by contacting MedPredict.
About MedPredict
MedPredict (http://www.medpredict.com) maintains a proprietary database of
over 1,000 global physician thought leaders. Based on primary interviews with
these thought leaders, MedPredict publishes periodic therapeutic area reports
to keep clients up-to-date on emerging trends and competitive activity. The
reports include thought leader reactions to recent publications and
presentations, as well as clinical, regulatory and marketing activity.
SOURCE MedPredict
Copyright © 2012, PRNewswire
Copyright © 2012, NewsBlaze,
Daily News
Search News
Daily News
